cCAM Biotherapeutics was focused on the discovery and development of novel cancer immunotherapies, with its lead product CM-24, a humanized monoclonal antibody, targeting the immune checkpoint protein CEACAM1. In 2015, cCAM Biotherapeutics was acquired by Merck.
Arkin Entry Stage
Pre Clinical
Status
M&A
Location
Misgav, IL
Let’s get in touch!
